Dr. Pedro Rosa-Neto

  1. Pichet Binette, A, Gonneaud, J, Vogel, JW, La Joie, R, Rosa-Neto, P, Collins, DL et al.. Morphometric network differences in ageing versus Alzheimer's disease dementia. Brain. 2020;143 (2):635-649. doi: 10.1093/brain/awz414. PubMed PMID:32040564 PubMed Central PMC7009528.
  2. Cisneros-Franco, JM, Voss, P, Kang, MS, Thomas, ME, Côté, J, Ross, K et al.. PET Imaging of Perceptual Learning-Induced Changes in the Aged Rodent Cholinergic System. Front Neurosci. 2019;13 :1438. doi: 10.3389/fnins.2019.01438. PubMed PMID:32038142 PubMed Central PMC6985428.
  3. Köbe, T, Gonneaud, J, Pichet Binette, A, Meyer, PF, McSweeney, M, Rosa-Neto, P et al.. Association of Vascular Risk Factors With β-Amyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use. JAMA Netw Open. 2020;3 (2):e1920780. doi: 10.1001/jamanetworkopen.2019.20780. PubMed PMID:32031648 .
  4. McSweeney, M, Pichet Binette, A, Meyer, PF, Gonneaud, J, Bedetti, C, Ozlen, H et al.. Intermediate flortaucipir uptake is associated with Aβ-PET and CSF-tau in asymptomatic adults. Neurology. 2020; :. doi: 10.1212/WNL.0000000000008905. PubMed PMID:32015176 .
  5. Dehghani, M, Zhang, S, Kumaragamage, C, Rosa-Neto, P, Near, J. Dynamic 1 H-MRS for detection of 13 C-labeled glucose metabolism in the human brain at 3T. Magn Reson Med. 2020; :. doi: 10.1002/mrm.28188. PubMed PMID:32003052 .
  6. Singleton, TA, Bdair, H, Bailey, JJ, Choi, S, Aliaga, A, Rosa-Neto, P et al.. Efficient radiosynthesis and preclinical evaluation of [18 F]FOMPyD as a positron emission tomography tracer candidate for TrkB/C receptor imaging. J Labelled Comp Radiopharm. 2020; :. doi: 10.1002/jlcr.3827. PubMed PMID:31919878 .
  7. Lussier, FZ, Pascoal, TA, Chamoun, M, Therriault, J, Tissot, C, Savard, M et al.. Mild behavioral impairment is associated with β-amyloid but not tau or neurodegeneration in cognitively intact elderly individuals. Alzheimers Dement. 2020;16 (1):192-199. doi: 10.1002/alz.12007. PubMed PMID:31914223 .
  8. Therriault, J, Benedet, AL, Pascoal, TA, Mathotaarachchi, S, Chamoun, M, Savard, M et al.. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β. JAMA Neurol. 2019; :. doi: 10.1001/jamaneurol.2019.4421. PubMed PMID:31860000 PubMed Central PMC6990684.
  9. Ng, KP, Chiew, HJ, Rosa-Neto, P, Kandiah, N, Ismail, Z, Gauthier, S et al.. Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia. Front Pharmacol. 2019;10 :1398. doi: 10.3389/fphar.2019.01398. PubMed PMID:31824321 PubMed Central PMC6882863.
  10. Ng, KP, Therriault, J, Kang, MS, Struyfs, H, Pascoal, TA, Mathotaarachchi, S et al.. Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy. Neuroimage Clin. 2019;24 :102091. doi: 10.1016/j.nicl.2019.102091. PubMed PMID:31795034 PubMed Central PMC6889764.
  11. Sharafi, SM, Sylvestre, JP, Chevrefils, C, Soucy, JP, Beaulieu, S, Pascoal, TA et al.. Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images. Alzheimers Dement (N Y). 2019;5 :610-617. doi: 10.1016/j.trci.2019.09.006. PubMed PMID:31650017 PubMed Central PMC6804547.
  12. Ng, KP, Richard-Devantoy, S, Bertrand, JA, Jiang, L, Pascoal, TA, Mathotaarachchi, S et al.. Suicidal ideation is common in autosomal dominant Alzheimer's disease at-risk persons. Int J Geriatr Psychiatry. 2020;35 (1):60-68. doi: 10.1002/gps.5215. PubMed PMID:31642105 .
  13. Hadoux, X, Hui, F, Lim, JKH, Masters, CL, Pébay, A, Chevalier, S et al.. Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease. Nat Commun. 2019;10 (1):4227. doi: 10.1038/s41467-019-12242-1. PubMed PMID:31530809 PubMed Central PMC6748929.
  14. Shin, J, Rowley, J, Chowdhury, R, Jolicoeur, P, Klein, D, Grova, C et al.. Inferior Longitudinal Fasciculus' Role in Visual Processing and Language Comprehension: A Combined MEG-DTI Study. Front Neurosci. 2019;13 :875. doi: 10.3389/fnins.2019.00875. PubMed PMID:31507359 PubMed Central PMC6716060.
  15. Ryu, JC, Zimmer, ER, Rosa-Neto, P, Yoon, SO. Consequences of Metabolic Disruption in Alzheimer's Disease Pathology. Neurotherapeutics. 2019;16 (3):600-610. doi: 10.1007/s13311-019-00755-y. PubMed PMID:31270743 PubMed Central PMC6694332.
  16. Cui, Y, Dai, S, Miao, Z, Zhong, Y, Liu, Y, Liu, L et al.. Reliability and Validity of the Chinese Version of the Mild Behavioral Impairment Checklist for Screening for Alzheimer's Disease. J. Alzheimers Dis. 2019;70 (3):747-756. doi: 10.3233/JAD-190113. PubMed PMID:31256131 .
  17. Therriault, J, Wang, S, Mathotaarachchi, S, Pascoal, TA, Parent, M, Beaudry, T et al.. Rostral-Caudal Hippocampal Functional Convergence Is Reduced Across the Alzheimer's Disease Spectrum. Mol. Neurobiol. 2019;56 (12):8336-8344. doi: 10.1007/s12035-019-01671-0. PubMed PMID:31230260 .
  18. Meyer, PF, Labonté, A, Rosa-Neto, P, Poirier, J, Breitner, JCS, PREVENT‐AD Research Group et al.. No apparent effect of naproxen on CSF markers of innate immune activation. Ann Clin Transl Neurol. 2019;6 (6):1127-1133. doi: 10.1002/acn3.788. PubMed PMID:31211178 PubMed Central PMC6562029.
  19. Miron, J, Picard, C, Lafaille-Magnan, MÉ, Savard, M, Labonté, A, Breitner, J et al.. Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation. Alzheimers Dement. 2019;15 (7):951-960. doi: 10.1016/j.jalz.2019.03.012. PubMed PMID:31175027 .
  20. Pascoal, TA, Mathotaarachchi, S, Kang, MS, Mohaddes, S, Shin, M, Park, AY et al.. Aβ-induced vulnerability propagates via the brain's default mode network. Nat Commun. 2019;10 (1):2353. doi: 10.1038/s41467-019-10217-w. PubMed PMID:31164641 PubMed Central PMC6547716.
  21. Liebsch, F, Kulic, L, Teunissen, C, Shobo, A, Ulku, I, Engelschalt, V et al.. Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. Nat Commun. 2019;10 (1):2240. doi: 10.1038/s41467-019-10152-w. PubMed PMID:31110178 PubMed Central PMC6527709.
  22. Bailey, JJ, Kaiser, L, Lindner, S, Wüst, M, Thiel, A, Soucy, JP et al.. First-in-Human Brain Imaging of [18F]TRACK, a PET tracer for Tropomyosin Receptor Kinases. ACS Chem Neurosci. 2019;10 (6):2697-2702. doi: 10.1021/acschemneuro.9b00144. PubMed PMID:31017386 .
  23. Lleó, A, Alcolea, D, Martínez-Lage, P, Scheltens, P, Parnetti, L, Poirier, J et al.. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimers Dement. 2019;15 (6):742-753. doi: 10.1016/j.jalz.2019.01.015. PubMed PMID:30967340 .
  24. Meyer, PF, Tremblay-Mercier, J, Leoutsakos, J, Madjar, C, Lafaille-Maignan, MÉ, Savard, M et al.. INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. Neurology. 2019;92 (18):e2070-e2080. doi: 10.1212/WNL.0000000000007232. PubMed PMID:30952794 PubMed Central PMC6512884.
  25. Miranda, A, Kang, MS, Blinder, S, Bouhachi, R, Soucy, JP, Aliaga-Aliaga, A et al.. PET imaging of freely moving interacting rats. Neuroimage. 2019;191 :560-567. doi: 10.1016/j.neuroimage.2019.02.064. PubMed PMID:30831313 .
  26. Liu, J, Wang, Q, Jing, D, Gao, R, Zhang, J, Cui, C et al.. Diagnostic Approach of Early-Onset Dementia with Negative Family History: Implications from Two Cases of Early-Onset Alzheimer's Disease with De Novo PSEN1 Mutation. J. Alzheimers Dis. 2019;68 (2):551-558. doi: 10.3233/JAD-181108. PubMed PMID:30814350 .
  27. Sheynin, Y, Chamoun, M, Baldwin, AS, Rosa-Neto, P, Hess, RF, Vaucher, E et al.. Cholinergic Potentiation Alters Perceptual Eye Dominance Plasticity Induced by a Few Hours of Monocular Patching in Adults. Front Neurosci. 2019;13 :22. doi: 10.3389/fnins.2019.00022. PubMed PMID:30766471 PubMed Central PMC6365463.
  28. Uribe, CF, Mathotaarachchi, S, Gaudet, V, Smith, KC, Rosa-Neto, P, Bénard, F et al.. Machine Learning in Nuclear Medicine: Part 1-Introduction. J. Nucl. Med. 2019;60 (4):451-458. doi: 10.2967/jnumed.118.223495. PubMed PMID:30733322 .
  29. Jiang, L, Oualkacha, K, Didelez, V, Ciampi, A, Rosa-Neto, P, Benedet, AL et al.. Constrained instruments and their application to Mendelian randomization with pleiotropy. Genet. Epidemiol. 2019;43 (4):373-401. doi: 10.1002/gepi.22184. PubMed PMID:30635941 PubMed Central PMC6537099.
  30. Carter, SF, Herholz, K, Rosa-Neto, P, Pellerin, L, Nordberg, A, Zimmer, ER et al.. Astrocyte Biomarkers in Alzheimer's Disease. Trends Mol Med. 2019;25 (2):77-95. doi: 10.1016/j.molmed.2018.11.006. PubMed PMID:30611668 .
  31. Schirrmacher, R, Bailey, JJ, Mossine, AV, Scott, PJH, Kaiser, L, Bartenstein, P et al.. Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging. Pharmaceuticals (Basel). 2019;12 (1):. doi: 10.3390/ph12010007. PubMed PMID:30609832 PubMed Central PMC6469173.
  32. Lam, J, DuBois, JM, Rowley, J, González-Otárula, KA, Soucy, JP, Massarweh, G et al.. In vivo metabotropic glutamate receptor type 5 abnormalities localize the epileptogenic zone in mesial temporal lobe epilepsy. Ann. Neurol. 2019;85 (2):218-228. doi: 10.1002/ana.25404. PubMed PMID:30597619 .
  33. Hopewell, R, Ross, K, Kostikov, A, Pascoal, TA, Alberti, T, Lacatus-Samoila, M et al.. A simplified radiosynthesis of [18 F]MK-6240 for tau PET imaging. J Labelled Comp Radiopharm. 2019;62 (2):109-114. doi: 10.1002/jlcr.3695. PubMed PMID:30426529 .
  34. Schilling, LP, Pascoal, TA, Zimmer, ER, Mathotaarachchi, S, Shin, M, de Mello Rieder, CR et al.. Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia. Mol. Neurobiol. 2019;56 (7):4916-4924. doi: 10.1007/s12035-018-1405-1. PubMed PMID:30414086 .
  35. Zhang, H, Ng, KP, Therriault, J, Kang, MS, Pascoal, TA, Rosa-Neto, P et al.. Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease. Transl Neurodegener. 2018;7 :23. doi: 10.1186/s40035-018-0127-7. PubMed PMID:30311914 PubMed Central PMC6161434.
  36. Ng, KP, Chiew, HJ, Lim, L, Rosa-Neto, P, Kandiah, N, Gauthier, S et al.. The influence of language and culture on cognitive assessment tools in the diagnosis of early cognitive impairment and dementia. Expert Rev Neurother. 2018;18 (11):859-869. doi: 10.1080/14737175.2018.1532792. PubMed PMID:30286681 .
  37. Zhang, H, Therriault, J, Kang, MS, Ng, KP, Pascoal, TA, Rosa-Neto, P et al.. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease. Alzheimers Res Ther. 2018;10 (1):80. doi: 10.1186/s13195-018-0407-6. PubMed PMID:30115118 PubMed Central PMC6097333.
  38. Gauthier, S, Herrmann, N, Rosa-Neto, P. Optimal use of cholinergic drugs in Alzheimer's disease. Brain. 2018;141 (9):e68. doi: 10.1093/brain/awy204. PubMed PMID:30084978 .
  39. Pascoal, TA, Shin, M, Kang, MS, Chamoun, M, Chartrand, D, Mathotaarachchi, S et al.. In vivo quantification of neurofibrillary tangles with [18F]MK-6240. Alzheimers Res Ther. 2018;10 (1):74. doi: 10.1186/s13195-018-0402-y. PubMed PMID:30064520 PubMed Central PMC6069775.
  40. Guadagno, A, Kang, MS, Devenyi, GA, Mathieu, AP, Rosa-Neto, P, Chakravarty, M et al.. Reduced resting-state functional connectivity of the basolateral amygdala to the medial prefrontal cortex in preweaning rats exposed to chronic early-life stress. Brain Struct Funct. 2018;223 (8):3711-3729. doi: 10.1007/s00429-018-1720-3. PubMed PMID:30032360 .
  41. Zukotynski, K, Kuo, PH, Mikulis, D, Rosa-Neto, P, Strafella, AP, Subramaniam, RM et al.. PET/CT of Dementia. AJR Am J Roentgenol. 2018;211 (2):246-259. doi: 10.2214/AJR.18.19822. PubMed PMID:29949415 .
  42. Smart, K, Cox, SML, Nagano-Saito, A, Rosa-Neto, P, Leyton, M, Benkelfat, C et al.. Test-retest variability of [11 C]ABP688 estimates of metabotropic glutamate receptor subtype 5 availability in humans. Synapse. 2018;72 (9):e22041. doi: 10.1002/syn.22041. PubMed PMID:29935121 .
  43. Gauthier, S, Zhang, H, Ng, KP, Pascoal, TA, Rosa-Neto, P. Impact of the biological definition of Alzheimer's disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?. Transl Neurodegener. 2018;7 :12. doi: 10.1186/s40035-018-0117-9. PubMed PMID:29876101 PubMed Central PMC5977549.
  44. Meyer, PF, Savard, M, Poirier, J, Labonté, A, Rosa-Neto, P, Weitz, TM et al.. Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis. J. Alzheimers Dis. 2018;63 (2):577-590. doi: 10.3233/JAD-170887. PubMed PMID:29660934 PubMed Central PMC5929310.
  45. Gauthier, S, Ng, KP, Pascoal, TA, Zhang, H, Rosa-Neto, P. Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment. J. Alzheimers Dis. 2018;64 (s1):S23-S31. doi: 10.3233/JAD-179924. PubMed PMID:29504543 PubMed Central PMC6004905.
  46. Villeneuve, S, Vogel, JW, Gonneaud, J, Pichet Binette, A, Rosa-Neto, P, Gauthier, S et al.. Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease. JAMA Neurol. 2018;75 (5):608-619. doi: 10.1001/jamaneurol.2017.5135. PubMed PMID:29482212 PubMed Central PMC5885216.
  47. Benedet, AL, Yu, L, Labbe, A, Mathotaarachchi, S, Pascoal, TA, Shin, M et al.. CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem. Neurol Genet. 2018;4 (1):e216. doi: 10.1212/NXG.0000000000000216. PubMed PMID:29473050 PubMed Central PMC5820598.
  48. Therriault, J, Ng, KP, Pascoal, TA, Mathotaarachchi, S, Kang, MS, Struyfs, H et al.. Anosognosia predicts default mode network hypometabolism and clinical progression to dementia. Neurology. 2018;90 (11):e932-e939. doi: 10.1212/WNL.0000000000005120. PubMed PMID:29444971 PubMed Central PMC5858945.
  49. Pascoal, TA, Mathotaarachchi, S, Shin, M, Park, AY, Mohades, S, Benedet, AL et al.. Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging. 2018;45 (6):1021-1030. doi: 10.1007/s00259-018-3933-3. PubMed PMID:29396637 PubMed Central PMC5915512.
  50. Henriques, AD, Benedet, AL, Camargos, EF, Rosa-Neto, P, Nóbrega, OT. Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to. Exp. Gerontol. 2018;107 :169-177. doi: 10.1016/j.exger.2018.01.002. PubMed PMID:29307736 .
  51. Bernard-Gauthier, V, Mossine, AV, Mahringer, A, Aliaga, A, Bailey, JJ, Shao, X et al.. Identification of [18F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging. J. Med. Chem. 2018;61 (4):1737-1743. doi: 10.1021/acs.jmedchem.7b01607. PubMed PMID:29257860 .
  52. Tardif, CL, Devenyi, GA, Amaral, RSC, Pelleieux, S, Poirier, J, Rosa-Neto, P et al.. Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease. Hum Brain Mapp. 2018;39 (2):971-984. doi: 10.1002/hbm.23897. PubMed PMID:29164798 .
  53. Li, X, Ba, M, Ng, KP, Mathotaarachchi, S, Pascoal, TA, Rosa-Neto, P et al.. Characterizing biomarker features of cognitively normal individuals with ventriculomegaly. Alzheimers Dement (Amst). 2018;10 :12-21. doi: 10.1016/j.dadm.2017.08.001. PubMed PMID:29159265 PubMed Central PMC5678356.
  54. Parent, MJ, Zimmer, ER, Shin, M, Kang, MS, Fonov, VS, Mathieu, A et al.. Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities. J. Neurosci. 2017;37 (50):12263-12271. doi: 10.1523/JNEUROSCI.1346-17.2017. PubMed PMID:29097597 PubMed Central PMC5729194.
  55. Gauthier, S, Ng, KP, Pascoal, TA, Mathotaarachchi, S, Chung, CO, Benedetti, AL et al.. Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology. 2017;89 (18):1931. doi: 10.1212/WNL.0000000000004593. PubMed PMID:29084927 .
  56. Ba, M, Li, X, Ng, KP, Pascoal, TA, Mathotaarachchi, S, Rosa-Neto, P et al.. The prevalence and biomarkers' characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database. Alzheimers Dement (N Y). 2017;3 (1):107-113. doi: 10.1016/j.trci.2016.12.005. PubMed PMID:29067322 PubMed Central PMC5651370.
  57. Tuwaig, M, Savard, M, Jutras, B, Poirier, J, Collins, DL, Rosa-Neto, P et al.. Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer's Disease. J. Alzheimers Dis. 2017;60 (4):1589-1600. doi: 10.3233/JAD-170545. PubMed PMID:28984583 PubMed Central PMC5757649.
  58. Aghourian, M, Legault-Denis, C, Soucy, JP, Rosa-Neto, P, Gauthier, S, Kostikov, A et al.. Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV. Mol. Psychiatry. 2017;22 (11):1531-1538. doi: 10.1038/mp.2017.183. PubMed PMID:28894304 .
  59. Mathotaarachchi, S, Pascoal, TA, Shin, M, Benedet, AL, Kang, MS, Beaudry, T et al.. Identifying incipient dementia individuals using machine learning and amyloid imaging. Neurobiol. Aging. 2017;59 :80-90. doi: 10.1016/j.neurobiolaging.2017.06.027. PubMed PMID:28756942 .
  60. Bernard-Gauthier, V, Bailey, JJ, Mossine, AV, Lindner, S, Vomacka, L, Aliaga, A et al.. A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human. J. Med. Chem. 2017;60 (16):6897-6910. doi: 10.1021/acs.jmedchem.7b00396. PubMed PMID:28696690 .
  61. Lafaille-Magnan, ME, Poirier, J, Etienne, P, Tremblay-Mercier, J, Frenette, J, Rosa-Neto, P et al.. Odor identification as a biomarker of preclinical AD in older adults at risk. Neurology. 2017;89 (4):327-335. doi: 10.1212/WNL.0000000000004159. PubMed PMID:28659431 PubMed Central PMC5574678.
  62. Engelborghs, S, Niemantsverdriet, E, Struyfs, H, Blennow, K, Brouns, R, Comabella, M et al.. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst). 2017;8 :111-126. doi: 10.1016/j.dadm.2017.04.007. PubMed PMID:28603768 PubMed Central PMC5454085.
  63. Dadar, M, Pascoal, TA, Manitsirikul, S, Misquitta, K, Fonov, VS, Tartaglia, MC et al.. Validation of a Regression Technique for Segmentation of White Matter Hyperintensities in Alzheimer's Disease. IEEE Trans Med Imaging. 2017;36 (8):1758-1768. doi: 10.1109/TMI.2017.2693978. PubMed PMID:28422655 .
  64. Ng, KP, Pascoal, TA, Mathotaarachchi, S, Chung, CO, Benedet, AL, Shin, M et al.. Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology. 2017;88 (19):1814-1821. doi: 10.1212/WNL.0000000000003916. PubMed PMID:28404803 PubMed Central PMC5419982.
  65. Chamoun, M, Huppé-Gourgues, F, Legault, I, Rosa-Neto, P, Dumbrava, D, Faubert, J et al.. Cholinergic Potentiation Improves Perceptual-Cognitive Training of Healthy Young Adults in Three Dimensional Multiple Object Tracking. Front Hum Neurosci. 2017;11 :128. doi: 10.3389/fnhum.2017.00128. PubMed PMID:28377707 PubMed Central PMC5359296.
  66. Ng, KP, Pascoal, TA, Mathotaarachchi, S, Therriault, J, Kang, MS, Shin, M et al.. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017;9 (1):25. doi: 10.1186/s13195-017-0253-y. PubMed PMID:28359327 PubMed Central PMC5374697.
  67. Zimmer, ER, Parent, MJ, Souza, DG, Leuzy, A, Lecrux, C, Kim, HI et al.. [18F]FDG PET signal is driven by astroglial glutamate transport. Nat. Neurosci. 2017;20 (3):393-395. doi: 10.1038/nn.4492. PubMed PMID:28135241 PubMed Central PMC5378483.
  68. Pascoal, TA, Mathotaarachchi, S, Shin, M, Benedet, AL, Mohades, S, Wang, S et al.. Synergistic interaction between amyloid and tau predicts the progression to dementia. Alzheimers Dement. 2017;13 (6):644-653. doi: 10.1016/j.jalz.2016.11.005. PubMed PMID:28024995 .
  69. Tam, A, Dansereau, C, Badhwar, A, Orban, P, Belleville, S, Chertkow, H et al.. A dataset of multiresolution functional brain parcellations in an elderly population with no or mild cognitive impairment. Data Brief. 2016;9 :1122-1129. doi: 10.1016/j.dib.2016.11.036. PubMed PMID:27924300 PubMed Central PMC5128734.
  70. Ba, M, Kong, M, Li, X, Ng, KP, Rosa-Neto, P, Gauthier, S et al.. Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease?. Transl Neurodegener. 2016;5 :20. doi: 10.1186/s40035-016-0067-z. PubMed PMID:27891223 PubMed Central PMC5112745.
  71. Mechling, AE, Arefin, T, Lee, HL, Bienert, T, Reisert, M, Ben Hamida, S et al.. Deletion of the mu opioid receptor gene in mice reshapes the reward-aversion connectome. Proc. Natl. Acad. Sci. U.S.A. 2016;113 (41):11603-11608. doi: 10.1073/pnas.1601640113. PubMed PMID:27671662 PubMed Central PMC5068324.
  72. DuBois, JM, Rousset, OG, Guiot, MC, Hall, JA, Reader, AJ, Soucy, JP et al.. Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging. Cereb. Cortex. 2016;26 (11):4170-4179. doi: 10.1093/cercor/bhw249. PubMed PMID:27578494 PubMed Central PMC5066831.
  73. Gibon, J, Kang, MS, Aliaga, A, Sharif, B, Rosa-Neto, P, Séguéla, P et al.. Towards the PET radiotracer for p75 neurotrophin receptor: [(11)C]LM11A-24 shows biological activity in vitro, but unfavorable ex vivo and in vivo profile. Bioorg. Med. Chem. 2016;24 (19):4759-4765. doi: 10.1016/j.bmc.2016.08.020. PubMed PMID:27567078 .
  74. Turgeon, M, Oualkacha, K, Ciampi, A, Miftah, H, Dehghan, G, Zanke, BW et al.. Principal component of explained variance: An efficient and optimal data dimension reduction framework for association studies. Stat Methods Med Res. 2018;27 (5):1331-1350. doi: 10.1177/0962280216660128. PubMed PMID:27460538 .
  75. Mathotaarachchi, S, Wang, S, Shin, M, Pascoal, TA, Benedet, AL, Kang, MS et al.. VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis. Front Neuroinform. 2016;10 :20. doi: 10.3389/fninf.2016.00020. PubMed PMID:27378902 PubMed Central PMC4908129.
  76. Cho, J, Kwon, DH, Kim, RG, Song, H, Rosa-Neto, P, Lee, MC et al.. Remodeling of Neuronal Circuits After Reach Training in Chronic Capsular Stroke. Neurorehabil Neural Repair. 2016;30 (10):941-950. doi: 10.1177/1545968316650282. PubMed PMID:27198184 .
  77. Gauthier, S, Rosa-Neto, P, Kass, JS. Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients. Continuum (Minneap Minn). 2016;22 (2 Dementia):615-8. doi: 10.1212/CON.0000000000000306. PubMed PMID:27042911 PubMed Central PMC5390936.
  78. Schilling, LP, Zimmer, ER, Shin, M, Leuzy, A, Pascoal, TA, Benedet, AL et al.. Imaging Alzheimer's disease pathophysiology with PET. Dement Neuropsychol. ;10 (2):79-90. doi: 10.1590/S1980-5764-2016DN1002003. PubMed PMID:29213438 PubMed Central PMC5642398.
  79. Pascoal, TA, Mathotaarachchi, S, Mohades, S, Benedet, AL, Chung, CO, Shin, M et al.. Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease. Mol. Psychiatry. 2017;22 (2):306-311. doi: 10.1038/mp.2016.37. PubMed PMID:27021814 PubMed Central PMC5262471.
  80. Laforce, R, Rosa-Neto, P, Soucy, JP, Rabinovici, GD, Dubois, B, Gauthier, S et al.. Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada. Can J Neurol Sci. 2016;43 (4):503-12. doi: 10.1017/cjn.2015.401. PubMed PMID:26916179 .
  81. Tam, A, Dansereau, C, Badhwar, A, Orban, P, Belleville, S, Chertkow, H et al.. Common Effects of Amnestic Mild Cognitive Impairment on Resting-State Connectivity Across Four Independent Studies. Front Aging Neurosci. 2015;7 :242. doi: 10.3389/fnagi.2015.00242. PubMed PMID:26733866 PubMed Central PMC4689788.
  82. Tomaszewski, S, Gauthier, S, Wimo, A, Rosa-Neto, P. Combination Therapy of Anti-Tau and Anti-Amyloid Drugs for Disease Modification in Early-stage Alzheimer's Disease: Socio-economic Considerations Modeled on Treatments for Tuberculosis, HIV/AIDS and Breast Cancer. J Prev Alzheimers Dis. 2016;3 (3):164-172. doi: 10.14283/jpad.2015.85. PubMed PMID:29205255 .
  83. Kim, RG, Cho, J, Ree, J, Kim, HS, Rosa-Neto, P, Kim, JM et al.. Sensory-parietal cortical stimulation improves motor recovery in severe capsular infarct. J. Cereb. Blood Flow Metab. 2016;36 (12):2211-2222. doi: 10.1177/0271678X15606136. PubMed PMID:26661148 PubMed Central PMC5363658.
  84. Benedet, AL, Labbe, A, Lemay, P, Zimmer, ER, Pascoal, TA, Leuzy, A et al.. Epistasis analysis links immune cascades and cerebral amyloidosis. J Neuroinflammation. 2015;12 :227. doi: 10.1186/s12974-015-0436-z. PubMed PMID:26626881 PubMed Central PMC4666175.
  85. Orban, P, Madjar, C, Savard, M, Dansereau, C, Tam, A, Das, S et al.. Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer's disease. Sci Data. 2015;2 :150043. doi: 10.1038/sdata.2015.43. PubMed PMID:26504522 PubMed Central PMC4603392.
  86. DuBois, JM, Rousset, OG, Rowley, J, Porras-Betancourt, M, Reader, AJ, Labbe, A et al.. Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [(11)C]ABP688 PET. Eur. J. Nucl. Med. Mol. Imaging. 2016;43 (1):152-162. doi: 10.1007/s00259-015-3167-6. PubMed PMID:26290423 .
  87. Zimmer, ER, Parent, MJ, Leuzy, A, Aliaga, A, Aliaga, A, Moquin, L et al.. Imaging in vivo glutamate fluctuations with [(11)C]ABP688: a GLT-1 challenge with ceftriaxone. J. Cereb. Blood Flow Metab. 2015;35 (7):1169-74. doi: 10.1038/jcbfm.2015.35. PubMed PMID:25806702 PubMed Central PMC4640271.
  88. Leuzy, A, Zimmer, ER, Dubois, J, Pruessner, J, Cooperman, C, Soucy, JP et al.. In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD. Brain Struct Funct. 2016;221 (3):1387-402. doi: 10.1007/s00429-014-0978-3. PubMed PMID:25596865 .
  89. Zimmer, ER, Leuzy, A, Gauthier, S, Rosa-Neto, P. Developments in Tau PET Imaging. Can J Neurol Sci. 2014;41 (5):547-53. doi: 10.1017/cjn.2014.15. PubMed PMID:25424608 .
  90. Bernard-Gauthier, V, Aliaga, A, Aliaga, A, Boudjemeline, M, Hopewell, R, Kostikov, A et al.. Syntheses and evaluation of carbon-11- and fluorine-18-radiolabeled pan-tropomyosin receptor kinase (Trk) inhibitors: exploration of the 4-aza-2-oxindole scaffold as Trk PET imaging agents. ACS Chem Neurosci. 2015;6 (2):260-76. doi: 10.1021/cn500193f. PubMed PMID:25350780 .
  91. Cyr, M, Parent, MJ, Mechawar, N, Rosa-Neto, P, Soucy, JP, Clark, SD et al.. Deficit in sustained attention following selective cholinergic lesion of the pedunculopontine tegmental nucleus in rat, as measured with both post-mortem immunocytochemistry and in vivo PET imaging with [¹⁸F]fluoroethoxybenzovesamicol. Behav. Brain Res. 2015;278 :107-14. doi: 10.1016/j.bbr.2014.09.021. PubMed PMID:25257103 .
  92. Zimmer, ER, Parent, MJ, Cuello, AC, Gauthier, S, Rosa-Neto, P. MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research. Trends Neurosci. 2014;37 (11):629-41. doi: 10.1016/j.tins.2014.07.002. PubMed PMID:25151336 .
  93. Zimmer, ER, Leuzy, A, Benedet, AL, Breitner, J, Gauthier, S, Rosa-Neto, P et al.. Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging. J Neuroinflammation. 2014;11 :120. doi: 10.1186/1742-2094-11-120. PubMed PMID:25005532 PubMed Central PMC4099095.
  94. Leuzy, A, Zimmer, ER, Heurling, K, Rosa-Neto, P, Gauthier, S. Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues. Amyloid. 2014;21 (3):143-8. doi: 10.3109/13506129.2014.926267. PubMed PMID:24919109 .
  95. Ongali, B, Nicolakakis, N, Tong, XK, Aboulkassim, T, Papadopoulos, P, Rosa-Neto, P et al.. Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model. Neurobiol. Dis. 2014;68 :126-36. doi: 10.1016/j.nbd.2014.04.018. PubMed PMID:24807206 .
  96. Milella, MS, Marengo, L, Larcher, K, Fotros, A, Dagher, A, Rosa-Neto, P et al.. Limbic system mGluR5 availability in cocaine dependent subjects: a high-resolution PET [(11)C]ABP688 study. Neuroimage. 2014;98 :195-202. doi: 10.1016/j.neuroimage.2014.04.061. PubMed PMID:24795154 .
  97. Zimmer, ER, Leuzy, A, Bhat, V, Gauthier, S, Rosa-Neto, P. In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals. Transl Neurodegener. 2014;3 (1):6. doi: 10.1186/2047-9158-3-6. PubMed PMID:24628994 PubMed Central PMC3995516.
  98. Wu, L, Soder, RB, Schoemaker, D, Carbonnell, F, Sziklas, V, Rowley, J et al.. Resting state executive control network adaptations in amnestic mild cognitive impairment. J. Alzheimers Dis. 2014;40 (4):993-1004. doi: 10.3233/JAD-131574. PubMed PMID:24583406 .
  99. Rosa-Neto, P, Hsiung, GY, Masellis, M, CCDTD4 participants. Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians. Alzheimers Res Ther. 2013;5 (Suppl 1):S8. doi: 10.1186/alzrt223. PubMed PMID:24565514 PubMed Central PMC3980280.
  100. Burhan, AM, Bartha, R, Bocti, C, Borrie, M, Laforce, R, Rosa-Neto, P et al.. Role of emerging neuroimaging modalities in patients with cognitive impairment: a review from the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther. 2013;5 (Suppl 1):S4. doi: 10.1186/alzrt200. PubMed PMID:24565285 PubMed Central PMC3981649.
Search PubMed